Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
US7557193B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 30, 2005 |
| Grant date | Jul 7, 2009 |
| Priority date | — |
| Expiry date | Jun 13, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a glycopeptide comprising between 1 and 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby the aforementioned polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes, and/or purified from biological fluids of human or animal origin or recombinant and produced by expression in a standard host cell comprising an enzymatic material necessary for priming a glycosylation, said host cell being genetically modified such as to comprise a gene coding for the aforementioned polypeptides and a gene coding for one or more enzymes selected from among glycosyltransferases and anti-glycopeptide antibodies. The invention also relates to the applications thereof in therapeutics and diagnostics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.